ADVENTRX Pharmaceuticals, Inc. (AMEX: ANX) CEO Discusses Oncology Programs at Conference
ADVENTRX Pharmaceuticals, Inc. (AMEX: ANX), a biopharmaceutical company focused on clinical development of antiviral and anticancer technologies, recently delivered a presentation at the Rodman & Renshaw 5th Annual Global Healthcare Conference in Monte Carlo. ADVENTRX Pharmaceuticals’ president and chief executive officer, Evan M. Levine, spoke at the convention, noting that the company is working to improve the performance and commercial potential of its existing therapies. Specifically targeting the oncology market, the company is currently focused on advancing its novel emulsion formulations of marketed chemotherapy drugs, ANX-530 (vinorelbine emulsion) and ANX-514 (docetaxel emulsion). ADVENTRX Pharmaceuticals plans to file NDAs for these…